Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Editorial note: This article is general medical education. Any clinical scenario, symptom pattern, medication, or genotype described is an illustrative composite used solely to explain pharmacologic and genetic principles. It does not describe, and is not derived from, any identifiable individual or protected health information.

Introduction: A Familiar but Unexplained Sleep Pattern

Consider a common but frequently misattributed pattern. A person falls asleep without difficulty, then wakes somewhere in the early-morning hours — alert, heart faintly pounding, mind suddenly racing — and cannot return to sleep. They take propranolol twice daily for anxiety, migraine prophylaxis, or essential tremor, and have often been told the sleep problem is "just stress." But what if the medication's pharmacokinetics, interacting with an individual's genetic profile, are the actual driver of this reproducible, clockwork-like awakening? This scenario is presented as a teaching illustration, not as a description of any particular individual.

This article presents a pharmacogenomic hypothesis — one that is mechanistically plausible and logically coherent, though not yet validated as a unified phenomenon in the published literature — for how immediate-release propranolol, combined with specific variants in the COMT, MAO-A, and DRD2 genes, may produce a drug-induced midnight catecholamine rebound that fragments sleep during the early morning hours.

Propranolol Pharmacokinetics: The 3-Hour Half-Life Problem

Immediate-release (IR) propranolol has an elimination half-life of approximately 3 to 6 hours [1–3]. This is a critically short duration when considered in the context of overnight dosing. For a client taking propranolol on a twice-daily (BID) schedule — with the evening dose administered around 8:00 or 9:00 PM — the drug reaches negligible plasma levels by approximately 1:30 to 4:00 AM. This is the precise window during which beta-adrenergic blockade dissipates, leaving the sympathetic nervous system functionally unblocked.

The clinical significance of this cannot be overstated. During the first half of the night, propranolol suppresses sympathetic tone, blocks catecholamine-driven arousal at the beta-adrenergic receptor, and even suppresses endogenous melatonin secretion via beta-1 receptor blockade on the pineal gland [17]. When the drug's plasma concentration drops below the therapeutic threshold in the early morning hours, the nervous system transitions from a pharmacologically suppressed state to an unsuppressed one — and it may not do so gracefully.

Beta-Blocker Rebound: More Than a Return to Baseline

Abrupt propranolol withdrawal is well-documented to cause beta-adrenergic receptor supersensitivity — not merely a return to baseline sympathetic tone, but a transient overshoot in catecholamine responsiveness [4–6]. This phenomenon has been studied most extensively in the context of complete drug cessation. Nattel and colleagues demonstrated that propranolol withdrawal produces transient supersensitivity to the chronotropic effects of isoproterenol, beginning 2 to 6 days after cessation, with associated increases in plasma catecholamines, heart rate, and blood pressure [5]. The ACCF/AHA guidelines explicitly note that heightened beta-receptor density and sensitivity after withdrawal can produce clinically significant rebound phenomena [4].

The classical rebound phenomenon unfolds over days. However, the concept of a nightly "micro-withdrawal" — a recurring mini-cessation as drug levels fall below the therapeutic threshold during the overnight dosing interval — is a pharmacodynamically rational extrapolation. While this specific nightly micro-cycle has not been formally studied, the underlying receptor pharmacology supports the plausibility: if the body upregulates beta-receptor sensitivity during the hours when the drug is absent, each night's drug trough could produce a miniature version of the withdrawal-rebound response.

The Genetic Amplifiers: COMT, MAO-A, and DRD2

Low COMT Activity: Impaired Catecholamine Clearance

Catechol-O-methyltransferase (COMT) is one of the primary enzymes responsible for extraneuronal degradation of catecholamines, particularly dopamine in the prefrontal cortex where dopamine transporter (DAT) expression is low [7, 8]. The Val158Met polymorphism (rs4680) produces a well-characterized functional difference: individuals homozygous for the Met allele (Met/Met) have a thermolabile, lower-activity COMT enzyme, resulting in slower catecholamine degradation.

In the context of the proposed midnight rebound, low COMT activity would amplify any catecholamine surge occurring during the drug-wearing-off period. If the propranolol trough triggers a sympathetic rebound, the norepinephrine and dopamine released during that surge would persist longer in the synaptic cleft due to impaired enzymatic clearance. Dauvilliers and colleagues have shown that the COMT Val158Met polymorphism influences sleep-wake regulation, EEG alpha oscillations, and recovery from sleep loss, though one large study (n = 4,625) found no significant impact on standard sleep quality measures — suggesting the effect may be conditional rather than universal [7, 9].

High MAO-A Activity: Oscillating Dynamics

Monoamine oxidase A (MAO-A) is the primary enzyme responsible for intraneuronal oxidative deamination of catecholamines [10, 8]. High MAO-A activity, associated with high-activity VNTR alleles, accelerates intraneuronal catecholamine degradation. Paradoxically, this may contribute to the proposed rebound mechanism rather than protect against it: rapid intraneuronal metabolism of norepinephrine by MAO-A could lead to lower tonic catecholamine stores, potentially upregulating postsynaptic receptor sensitivity as a compensatory response.

An important nuance deserves attention here. Brummett and colleagues found that low MAO-A activity alleles — not high — were associated with poorer sleep quality and increased depressive symptoms [11]. This finding creates legitimate friction with the proposed model and warrants intellectual honesty. The interaction between MAO-A and COMT is complex: with low COMT, catecholamine metabolism shifts more toward the MAO pathway, and high MAO-A activity in this context could create oscillating catecholamine dynamics — rapid intraneuronal depletion followed by extraneuronal persistence — rather than steady-state levels. This oscillation, rather than simple elevation, may be what destabilizes sleep architecture.

DRD2 Hyperreceptivity: The Arousal Amplifier

The dopamine D2 receptor system plays an essential role in wakefulness maintenance. D2 receptor knockout mice show decreased wakefulness and increased sleep fragmentation, while dopaminergic surges via the VTA-mPFC pathway disrupt NREM sleep spindles and cause sleep fragmentation [12, 13]. The DRD2/ANKK1 Taq1A A1 allele is associated with reduced striatal D2 receptor density — approximately 5 to 12 percent lower binding — which could paradoxically lead to compensatory postsynaptic hypersensitivity [14, 15].

Critically, the A1A1 homozygous genotype has been directly associated with sleep dysfunction in a study by Jiang and colleagues, with an odds ratio of 2.90 (95% CI: 1.75–4.82) [16]. If "hyperreceptivity" refers to this compensatory upregulation of D2 signaling in the setting of lower receptor density, any nocturnal dopamine surge — even a modest one triggered by the propranolol trough — would produce an exaggerated arousal response.

The Integrated Mechanism: A Five-Step Cascade

When these individual pharmacological and genetic components are synthesized, the proposed mechanism operates as a sequential cascade:

Step 1: Drug Trough. Propranolol IR taken in the evening wears off by approximately 1:30 AM (3 to 5 half-lives from a 9:00 PM dose), leaving the sympathetic nervous system functionally unblocked.

Step 2: Beta-Receptor Supersensitivity. As beta-blockade dissipates, upregulated receptor sensitivity amplifies the sympathetic and catecholamine response beyond baseline — a nightly micro-rebound.

Step 3: Impaired Catecholamine Clearance (Low COMT). The Met/Met genotype impairs extraneuronal catecholamine degradation, prolonging the norepinephrine and dopamine surge in the synaptic cleft.

Step 4: Oscillating Catecholamine Dynamics (High MAO-A). Rapid intraneuronal catecholamine metabolism creates depletion-repletion oscillations and compensatory receptor changes that further destabilize the catecholaminergic milieu.

Step 5: Exaggerated Arousal Response (DRD2 Hyperreceptivity). Compensatory D2 postsynaptic hypersensitivity from reduced receptor density amplifies the wake signal from any dopamine surge, fragmenting sleep during the vulnerable early-morning hours.

Additionally, propranolol itself suppresses melatonin secretion via beta-1 receptor blockade on the pineal gland [17]. This pharmacological suppression of the primary sleep-promoting hormone could further lower the arousal threshold during the already-vulnerable overnight trough period.

An Important Nuance: Micro-Rebound vs. Unmasking

While the integrated cascade described above is pharmacologically coherent, one contextual nuance regarding receptor kinetics warrants careful consideration. Beta-receptor upregulation — the driver of true rebound supersensitivity — generally takes days to develop and days to resolve. The 1:30 AM awakenings may therefore not represent a true hyper-sensitized rebound in the classical sense, but rather the unmasking of the client's baseline high sympathetic tone — the very condition for which propranolol was originally prescribed — as the drug's plasma concentration falls below the therapeutic threshold.

Both mechanisms lead to the same clinical outcome (early-morning wakefulness), and both respond to the same therapeutic strategies. The distinction matters primarily for mechanistic precision, not for clinical management.

Clinical Strategies: What Can Be Done

If this mechanism is contributing to the described sleep pattern, several evidence-informed strategies merit consideration:

Long-acting propranolol formulation (Inderal LA). Extended-release formulations maintain more stable plasma levels over 24 hours, eliminating the overnight trough that triggers the proposed rebound [18].

Switch to a hydrophilic beta-blocker (e.g., atenolol). Hydrophilic beta-blockers do not cross the blood-brain barrier as readily as lipophilic propranolol, resulting in significantly fewer nocturnal awakenings. One controlled trial demonstrated 3.6 awakenings with atenolol versus 6.3 with propranolol [19, 20].

Adjusted dose timing. A later evening dose or the addition of a small bedtime dose could extend beta-blockade coverage through the vulnerable early-morning window.

Alternative drug class. Depending on the clinical indication, the beta-blocker may be replaceable with an agent that does not produce the same overnight pharmacokinetic trough — a decision that requires individualized clinical evaluation.

Verdict: Highly Plausible but Speculative

This is a thoughtful pharmacogenomic hypothesis, and each individual component rests on established evidence. Propranolol's short half-life is well-characterized. Beta-blocker rebound is clinically documented. COMT Met/Met genotype impairs catecholamine clearance. DRD2 A1A1 genotype is associated with sleep dysfunction. Propranolol suppresses melatonin. However, no published study has specifically examined the interaction of COMT, MAO-A, and DRD2 genotypes with propranolol BID dosing and nocturnal sleep fragmentation patterns as a unified phenomenon.

The hypothesis is mechanistically inferred rather than empirically demonstrated — but it is precisely this kind of pharmacogenomic reasoning that drives the next generation of personalized medicine. In general terms, when a reproducible sleep-disruption pattern aligns with a drug's pharmacokinetic trough, and when genetic variants are present that would be expected to amplify catecholamine-driven arousal in that window, a clinician has a reasonable, individualized basis to consider therapeutic adjustment — even in the absence of a randomized controlled trial designed to test this specific gene-drug interaction. Any such decision belongs in a private, one-on-one clinical evaluation, not in general educational content like this article.

References

1. Propranolol Hydrochloride. Food and Drug Administration. Updated 2026-01-12.

2. Propranolol hydrochloride. Food and Drug Administration. Updated 2026-02-02.

3. Shand DG. Pharmacokinetics of Propranolol: A Review. Postgraduate Medical Journal. 1976;52 Suppl 4:22-25.

4. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Journal of the American College of Cardiology. 2012;60(24):e44-e164. doi:10.1016/j.jacc.2012.07.013.

5. Nattel S, Rangno RE, Van Loon G. Mechanism of Propranolol Withdrawal Phenomena. Circulation. 1979;59(6):1158-64. doi:10.1161/01.cir.59.6.1158.

6. Rangno RE, Langlois S. Comparison of Withdrawal Phenomena After Propranolol, Metoprolol and Pindolol. British Journal of Clinical Pharmacology. 1982;13(Suppl 2):345S-351S. doi:10.1111/j.1365-2125.1982.tb01939.x.

7. Dauvilliers Y, Tafti M, Landolt HP. Catechol-O-Methyltransferase, Dopamine, and Sleep-Wake Regulation. Sleep Medicine Reviews. 2015;22:47-53. doi:10.1016/j.smrv.2014.10.006.

8. Tunbridge EM, Narajos M, Harrison CH, et al. Which Dopamine Polymorphisms Are Functional? Systematic Review and Meta-Analysis. Biological Psychiatry. 2019;86(8):608-620. doi:10.1016/j.biopsych.2019.05.014.

9. Jawinski P, Tegelkamp S, Sander C, et al. Time to Wake Up: No Impact of COMT Val158Met Gene Variation on Circadian Preferences, Arousal Regulation and Sleep. Chronobiology International. 2016;33(7):893-905. doi:10.1080/07420528.2016.1178275.

10. Goldstein DS, Castillo G, Sullivan P, Sharabi Y. Differential Susceptibilities of Catecholamines to Metabolism by Monoamine Oxidases. The Journal of Pharmacology and Experimental Therapeutics. 2021;379(3):253-259. doi:10.1124/jpet.121.000826.

11. Brummett BH, Krystal AD, Siegler IC, et al. Associations of a Regulatory Polymorphism of Monoamine Oxidase-A Gene Promoter (MAOA-uVNTR) With Symptoms of Depression and Sleep Quality. Psychosomatic Medicine. 2007;69(5):396-401. doi:10.1097/PSY.0b013e31806d040b.

12. Qu WM, Xu XH, Yan MM, et al. Essential Role of Dopamine D2 Receptor in the Maintenance of Wakefulness, but Not in Homeostatic Regulation of Sleep, in Mice. The Journal of Neuroscience. 2010;30(12):4382-9. doi:10.1523/JNEUROSCI.4936-09.2010.

13. Li R, Zhang X, Li J, et al. Hyperexcitable VTA-mPFC Dopaminergic Circuit Disrupts Sleep Spindle and Mediates Sleep Fragmentation After Chronic Social Defeat Stress. Neuron. 2026;:S0896-6273(26)00332-6. doi:10.1016/j.neuron.2026.04.037.

14. Gluskin BS, Mickey BJ. Genetic Variation and Dopamine D2 Receptor Availability: A Systematic Review and Meta-Analysis. Translational Psychiatry. 2016;6:e747. doi:10.1038/tp.2016.22.

15. Eisenstein SA, Bogdan R, Love-Gregory L, et al. Prediction of Striatal D2 Receptor Binding by DRD2/ANKK1 TaqIA Allele Status. Synapse. 2016;70(10):418-31. doi:10.1002/syn.21916.

16. Jiang Y, Liu B, Wu C, et al. Dopamine Receptor D2 Gene (DRD2) Polymorphisms, Job Stress, and Their Interaction on Sleep Dysfunction. International Journal of Environmental Research and Public Health. 2020;17(21):E8174. doi:10.3390/ijerph17218174.

17. Pope E. Commentary: Beta-blockers and Sleep Problems. Pediatric Dermatology. 2021;38(2):378-379. doi:10.1111/pde.14537.

18. INDERAL LA. Food and Drug Administration. Updated 2024-08-01.

19. Kostis JB, Rosen RC. Central Nervous System Effects of Beta-Adrenergic-Blocking Drugs: The Role of Ancillary Properties. Circulation. 1987;75(1):204-12. doi:10.1161/01.cir.75.1.204.

20. Betts TA, Alford C. Beta-Blockers and Sleep: A Controlled Trial. European Journal of Clinical Pharmacology. 1985;28 Suppl:65-8. doi:10.1007/BF00543712.

About Dr. Kim

Dr. Yoon Hang "John" Kim is a board-certified physician (Preventive Medicine) and Integrative & Functional Medicine specialist with over 20 years of clinical experience. He completed fellowship training at the University of Arizona under Dr. Andrew Weil (Osher Fellow) and holds additional certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. He specializes in low dose naltrexone (LDN) therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of three books and over 20 published articles. For more information, visit www.yoonhangkim.com or www.directintegrativecare.com.